2. Academic Validation
  3. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis

A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis

  • J Am Acad Dermatol. 2021 Apr;84(4):1160-1162. doi: 10.1016/j.jaad.2020.07.122.
Yoo Jung Kim 1,  Elena Schiopu 2,  Katalin Dankó 3,  Tahseen Mozaffar 4,  Srinivas Chunduru 5,  Kirstin Lees 5,  Namita A Goyal 4,  Jeffrey Sarazin 2,  David F Fiorentino 6,  Kavita Y Sarin 7
Affiliations

Affiliations

  • 1 Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
  • 2 Department of Rheumatology, University of Michigan, Ann Arbor, Michigan.
  • 3 Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary.
  • 4 Department of Neurology, University of California Irvine, Irvine, California.
  • 5 Idera Pharmaceuticals, Inc, Exton, Pennsylvania.
  • 6 Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: fiorentino@stanford.edu.
  • 7 Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: ksarin@stanford.edu.
PMID: 32781178 DOI: 10.1016/j.jaad.2020.07.122
Figures
Products